{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:36:31Z","timestamp":1788870991017,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T00:00:00Z","timestamp":1427241600000},"content-version":"vor","delay-in-days":52,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jns.2014.12.030","type":"journal-article","created":{"date-parts":[[2014,12,27]],"date-time":"2014-12-27T11:46:20Z","timestamp":1419680780000},"page":"84-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE)"],"prefix":"10.1016","volume":"349","author":[{"given":"Joseph","family":"Jankovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Comella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrey","family":"Manack Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jns.2014.12.030_bb0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: a consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.jns.2014.12.030_bb0010","first-page":"1","article-title":"Descriptive epidemiology of cervical dystonia","volume":"3","author":"Defazio","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"4","key":"10.1016\/j.jns.2014.12.030_bb0015","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mds.10127","article-title":"Impact of cervical dystonia on quality of life","volume":"17","author":"Camfield","year":"2002","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.jns.2014.12.030_bb0020","first-page":"95","article-title":"Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections","volume":"22","author":"Slawek","year":"2007","journal-title":"Funct Neurol"},{"issue":"7","key":"10.1016\/j.jns.2014.12.030_bb0025","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00415-002-0733-1","article-title":"The impact of blepharospasm and cervical dystonia on health-related quality of life and depression","volume":"249","author":"M\u00fcller","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2014.12.030_bb0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"issue":"2","key":"10.1016\/j.jns.2014.12.030_bb0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/toxins5020249","article-title":"Long-term efficacy and safety of botulinum toxin injections in dystonia","volume":"5","author":"Ramirez-Castaneda","year":"2013","journal-title":"Toxins (Basel)"},{"issue":"5","key":"10.1016\/j.jns.2014.12.030_bb0040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/WNF.0b013e31826538c7","article-title":"Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia","volume":"35","author":"Charles","year":"2012","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"10.1016\/j.jns.2014.12.030_bb0045","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jns.2014.12.030_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13311-013-0221-6","article-title":"Designing clinical trials for dystonia","volume":"11","author":"Galpern","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jns.2014.12.030_bb0055","series-title":"Epidemiology - Current Perspectives on Research and Practice","article-title":"Role of epidemiological data within the drug development lifecycle: a chronic migraine case study","author":"Manack","year":"2012"},{"key":"10.1016\/j.jns.2014.12.030_bb0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2377-11-140","article-title":"Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)","volume":"11","author":"Jankovic","year":"2011","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.jns.2014.12.030_bb0065","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mds.870120414","article-title":"Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale","volume":"12","author":"Comella","year":"1997","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.jns.2014.12.030_bb0070","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/mds.25579","article-title":"Dystonia rating scales: critique and recommendations","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.jns.2014.12.030_bb0075","series-title":"Therapy with botulinum toxin","first-page":"211","article-title":"Clinical assessments of patients with cervical dystonia","author":"Consky","year":"1994"},{"key":"10.1016\/j.jns.2014.12.030_bb0080","series-title":"Manual for the ECDEU assessment battery","year":"1976"},{"issue":"12","key":"10.1016\/j.jns.2014.12.030_bb0085","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/jama.282.12.1157","article-title":"Capturing the patient's view of change as a clinical outcome measure","volume":"282","author":"Fischer","year":"1999","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jns.2014.12.030_bb0090","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1212\/01.WNL.0000142962.11881.26","article-title":"Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58)","volume":"63","author":"Cano","year":"2004","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jns.2014.12.030_bb0095","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/01.wnl.0000249310.25427.f2","article-title":"CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia","volume":"67","author":"Cano","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2014.12.030_bb0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"issue":"1\u20132","key":"10.1016\/j.jns.2014.12.030_bb0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.jns.2014.12.030_bb0110","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia","volume":"16","author":"Truong","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"10.1016\/j.jns.2014.12.030_bb0115","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2014.12.030_bb0120","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2014.12.030_bb0125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.jns.2014.12.030_bb0130","series-title":"BOTOX\u00ae summary of product characteristics","year":"2013"},{"issue":"5","key":"10.1016\/j.jns.2014.12.030_bb0135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","article-title":"Long-term botulinum toxin efficacy, safety, and immunogenicity","volume":"20","author":"Mejia","year":"2005","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.jns.2014.12.030_bb0140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.cgh.2013.03.006","article-title":"Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C","volume":"11","author":"Belperio","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jns.2014.12.030_bb0145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor \u03b1 drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14007953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14007953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:44:05Z","timestamp":1758383045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X14007953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":29,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0022510X14007953"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2014.12.030","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE)","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2014.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V.","name":"copyright","label":"Copyright"}]}}